Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
Amicus Therapeutics (FOLD) has scheduled its first quarter 2025 financial results conference call and audio webcast for Thursday, May 1, 2025, at 8:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amicus Therapeutics (FOLD) has scheduled its first quarter 2025 financial results conference call and audio webcast for Thursday, May 1, 2025, at 8:30 a.m. ET. The event will cover financial performance for Q1 ending March 31, 2025.
Participants must pre-register online to receive dial-in details and a personal PIN for phone access. A live webcast and presentation materials will be available through the Investors section at ir.amicusrx.com, with recommended registration 15 minutes before the call. An archived version and slides will be accessible post-event on the company website.
Details
News Market Reaction – FOLD
The recorded move for FOLD in the trading session of this news was -1.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025.
Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.
An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.